Johnson & Johnson receives positive CHMP opinion recommending full approval for SIRTURO® (bedaquiline) for treatment of multidrug-resistant TB

-- CHMP recommends Conditional Marketing Authorisation be converted into standard Marketing Authorisation

-- Recommendation supported by results from the Phase 3 STREAM Stage 2 study, which show bedaquiline-containing regimens offer significant improvement compared to other available therapies